Investing.com - Leerink Partners重申对 Structure Therapeutics (NASDAQ:GPCR) ...

Investing.com - Stifel在 Structure Therapeutics (NASDAQ:GPCR) 公布新临床试验数据后,重申买入评级和$90目标价。该股现报$57.42,市值38.1亿美元,较52周高点$94.90下跌39%,但过去一年仍录得155%的涨幅。根据 InvestingPro 分析,该股目前相对其公允价值似乎 估值过高 。

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for chronic weight ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

Structure Therapeutics (GPCR) has drawn attention after recent share price swings, including a month return of a 27.7% decline and a past 3 months gain of 80.8%, prompting investors to reassess its ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...